Introduction {#S1}
============

Keratitis due to yeasts and filamentous fungi is a serious health issue in tropical and subtropical countries. In South India, it is among the leading causes of ocular morbidity and corneal blindness ([@B8]; [@B41]), that could be avoidable with a timely diagnosis and a subsequent appropriate antifungal therapy ([@B18]). Fungal keratitis typically affects middle-aged men having agriculture-related or other outdoor occupations in developing countries. While trauma has been the key predisposing factor, diabetes mellitus, contact lens wear, corticosteroid therapy, a prior eye surgery or eye disease are also among the frequently reported other risk factors for the infection ([@B7]; [@B43]; [@B44]; [@B39]). Among filamentous fungal aetiologies, the genera *Fusarium* (31--52.5%) and *Aspergillus* (11--41%) are the main pathogens ([@B12]; [@B39]; [@B31]). The spectrum of *Aspergillus* species identified from keratitis cases is relatively wide. While *A. flavus* is the most common cause of *Aspergillus* keratitis, *A. fumigatus*, *A. terreus* ([@B24]), *A. brasiliensis* ([@B32]), *A. nomius* ([@B34]), *A. pseudotamarii* ([@B6]), *A. tamarii* ([@B25]; [@B33]; [@B17]; [@B14]; [@B1]; [@B31]), and *A. tubingensis* ([@B26]) were also reported sporadically from human keratomycoses.

*Aspergillus tamarii* is a member of the *Aspergillus* section *Flavi*. It is widely used in the food and fermentation industries ([@B45]). At the same time, it has been more commonly recognized from human infections in the last 15 years. In addition to keratitis, this species has been reported from an eyelid infection ([@B15]), onychomycosis ([@B27]), cutaneous infections ([@B40]; [@B23]), a wound infection ([@B4]), an invasive nasosinusal aspergillosis ([@B38]), a nasal polyposis ([@B21]) and respiratory tract samples ([@B42]; [@B9]). It is a non-aflatoxigenic species, although, its representatives are known for their cyclopiazonic acid (CPA), fumigaclavin and kojic acid producing ability ([@B45]).

Because of the small number of cases where molecular identification, antifungal susceptibilities and clinical data are all provided at the same time, clinical breakpoints and even epidemiological cutoff values are not available for this species. In order to determine the clinical relevance of identifying *A. tamarii* at the species level, studies like the present work are necessary. Here, we report and characterize six *A. tamarii* isolates from keratitis, and also provide a review of the relating English-language literature. Our specific goals were to compare and discuss the reliability of morphological and molecular identification methods in case of *A. tamarii*, to determine the antifungal susceptibility profiles of the isolates, to study the *in vitro* efficacy of clinically relevant dual drug combinations against the isolates, to examine the relationship between the *in vitro* antifungal susceptibility and the outcome of therapies, to determine the CPA producing ability of the strains, and finally, to compare our observations to the relevant literature of the field.

Materials and Methods {#S2}
=====================

Molecular Identification {#S2.SS1}
------------------------

Six isolates of *Aspergillus* spp., obtained after processing the corneal scrapings from the suspected fungal keratitis patients attending the Cornea Services at Aravind Eye Hospital and Postgraduate Institute of Ophthalmology (Coimbatore, Tamil Nadu, India) during 2005 and 2007 and identified based on the initial morphological examinations (i.e., KOH wet mount of corneal scrapings, growth on 5% sheep blood agar, chocolate agar and potato dextrose agar, and micromorphology of the cultures after lactophenol cotton blue staining), were included in the study. For the species-level identification using molecular methods, the internal transcribed spacer (ITS) region and a part of the calmodulin gene were amplified using the ITS1/ITS4 and cmd5/cmd6 primer pairs, respectively, as described earlier ([@B46]; [@B19]). The sequences were determined at LGC Genomics GmbH (Berlin, Germany) and were deposited in the GenBank database under the accession numbers listed in [Table 1](#T1){ref-type="table"}. BLAST searches were conducted against the GenBank database at the website of the National Center for Biotechnology Information^[1](#footnote1){ref-type="fn"}^ ([@B2]).

###### 

Results of the identification of *Aspergillus* spp. from keratitis.

  **Case**   **Strain number**   **ITS**    **Calmodulin**   **Species based on**                                                           
  ---------- ------------------- ---------- ---------------- ---------------------- ----- ------------------- ----------------------------- --------------
  1          SZMC 2393           MG907190   522              MG912921               520   *A. flavus*         *A. tamarii*                  *A. tamarii*
  2          SZMC 2404           MG907191   521              MG912922               516   *A. flavus*         *A. tamarii* or *A. nomius*   *A. tamarii*
  3          SZMC 2428           MG907192   521              MG912923               516   *Aspergillus* sp.   *A. tamarii*                  *A. tamarii*
  4          SZMC 2434           MG907193   530              MG912924               516   *A. flavus*         *A. tamarii*                  *A. tamarii*
  5          SZMC 2438           MG907194   532              MG912925               516   *A. flavus*         *A. tamarii*                  *A. tamarii*
  6          SZMC 2439           MG907195   535              MG912926               516   *A. fumigatus*      *A. tamarii*                  *A. tamarii*

ITS, internal transcribed spacer; SZMC, Szeged Microbiological Collection, University of Szeged, Szeged, Hungary.

All the six isolates have been deposited at the Szeged Microbiology Collection (SZMC, Szeged, Hungary^[2](#footnote2){ref-type="fn"}^) under the accession numbers of SZMC 2393, SZMC 2404, SZMC 2428, SZMC 2434, SZMC 2438, and SZMC 2439.

Antifungal Susceptibility Testing {#S2.SS2}
---------------------------------

Determination of antifungal susceptibility profiles of the six isolates was performed according to the guidelines of the CLSI M38-A2 broth microdilution method ([@B13]). Eight clinically relevant antifungal agents, such as amphotericin B, natamycin, clotrimazole, econazole, fluconazole, itraconazole, ketoconazole and terbinafine (Sigma-Aldrich, United States) were included in the study. The final concentration range of amphotericin B, clotrimazole, econazole, fluconazole, ketoconazole and natamycin was 0.125--64 μg/ml, while in case of itraconazole and terbinafine, the tested concentrations ranged between 0.002 and 1 μg/ml. Microdilution test plates were evaluated after 48 h of incubation at 35°C. All plates were read spectrophotometrically, and the results were also verified by visual examination. As it is recommended by the CLSI guidelines, for amphotericin B, clotrimazole, econazole, and itraconazole, the MICs were read as the lowest concentrations that prevented any discernible growth (100% inhibition). The MICs of fluconazole and ketoconazole were determined as the lowest concentration of the drug that caused approximately 50% reduction in growth compared to the growth observed in the drug-free medium. While in case of terbinafine, the turbidity allowed corresponded to 80% or more reduction in growth compared to the control well ([@B13]).

Drug Interaction Tests {#S2.SS3}
----------------------

Antifungal drug combinations were investigated using the checkerboard microdilution method ([@B35]) between the commonly applied combinations of antifungals in *A. tamarii* keratitis presented in [Table 2](#T2){ref-type="table"}, viz., natamycin-econazole, natamycin-itraconazole, and econazole-itraconazole. Antifungal drug dilutions and inocula were prepared based on the CLSI methodology. The final concentration ranges of econazole, itraconazole and natamycin were 2--64, 0.01--0.25, and 0.03--1 μg/ml, respectively. All plates were read spectrophotometrically, and the results were verified by visual examination. Drug interactions were assessed after 48 h incubation based on the fractional inhibitory concentration index (FICI) calculated for all of the wells that corresponded to a MIC. Synergism was defined as FICI ≤ 0.5, 0.5 ≤ FICI ≤ 4 indicated indifference, whereas antagonism was defined as FICI ≥ 4 ([@B37]).

###### 

Detailed characteristics of the six newly presented cases of keratitis caused by *Aspergillus tamarii* and their comparison to previously reported cases.

  **Case no.**   **State, country**   **Age/sex**   **Month of presentation**   **Prior surgery**                          **Eye/symptoms**                               **Gram- stain/KOH/PAS**   **Injury/risk factor**          **Ulcer severity**   **Hypopyon**   **VA**   **Antifungal therapy**   **Complications**          **Outcome**   **References**                                                         
  -------------- -------------------- ------------- --------------------------- ------------------------------------------ ---------------------------------------------- ------------------------- ------------------------------- -------------------- -------------- -------- ------------------------ -------------------------- ------------- --------------------------------- ------------------------------------ ------------
  Case 1         TN, India            75/F          July                        Cataract/IOL                               LE/defective vision, pain, redness             \+                        No                              Severe               Yes            LP       NA                       NTM, ECN (then CLT), ITC   KTC           Assumed bacterial coinfection     Good response, no follow-up          This study
  Case 2         TN, India            60/F          September                   No                                         LE/redness, pain, watering, defective vision   \+                        No                              Severe               No             2/60     2/60                     NTM, ECN (then CLT), ITC   KTC           No                                Healed, no follow-up                 This study
  Case 3         K, India             88/M          May                         SBCS/IOL                                   RE/defective vision, pain, redness             −                         No                              Severe               Yes            LP       NA                       NTM, ECN, ITC, AMB         KTC           Bacterial coinfection, vitritis   Evisceration                         This study
  Case 4         TN, India            75/F          June                        No                                         RE/watering, pain, defective vision            −                         Dust                            Mild                 No             6/24     6/18                     NTM, ITC                   No            No                                Healed                               This study
  Case 5         TN, India            40/F          June                        No                                         RE/redness, pain and watering                  \+                        Insect                          Mild                 No             6/12     6/24                     NTM, ECN, ITC              KTC           No                                Healed                               This study
  Case 6         TN, India            48/M          June                        No                                         LE/pain, photophobia, defective vision         \+                        Mud                             Severe               Yes            6/24     NA                       NTM, ECN, ITC              KTC           No                                No response, no follow-up            This study
  NA             TN, India            32/F          December                    No                                         LE/pain, redness, defective vision             \+                        Iron piece                      NA                   Yes            1/2/60   6/12                     NTM, ECN, FLC              KTC           No                                Improved, central nebular scar       [@B25]
  NA             Spain                NA/M          August                      LASIK, CRI, vitrectomy, scleral buckling   LE/blurred vision, pain, discharge             \+                        No injury/contact lens wearer   NA                   Yes            6/60     NA                       VRC, AMB, NTM              AMB, VRC      No                                Improved, extensive corneal scar     [@B14]
  Patient 4      Mexico               NA/M          NA                          No                                         RE/NA                                          \+                        NA                              NA                   NA             HM       6/12                     VRC                        ITC           NA                                Improved, no surgery                 [@B1]
  Patient 16     Mexico               51/M          NA                          No                                         LE/NA                                          −                         NA                              NA                   NA             HM       LP                       VRC after surgery          No            NA                                Tectonic KP, vitrectomy              [@B1]
  Patient 17     Mexico               51/M          NA                          No                                         LE/NA                                          \+                        NA                              NA                   NA             HM       LP                       VRC after surgery          No            NA                                Tectonic KP, vitrectomy              [@B1]
  Patient 20     Mexico               32/F          NA                          No                                         RE/NA                                          \+                        NA                              NA                   NA             6/60     NA                       VRC                        No            NA                                Tectonic KP, OKP, intraocular lens   [@B1]

AMB, amphotericin B; CLT, clotrimazole; CRI, corneal ring implantation; ECN, econazole; F, female; HM, hand motion; IOL, intraocular lens implantation; ITC, itraconazole; LE, left eye; LP, light perception; K, Kerala; KP, keratoplasty; KTC, ketoconazole; LASIK, laser

in situ

keratomileusis; M, male; NA, not available; NTM, natamycin; OKP, optical keratoplasty; PAS, Periodic acid-Schiff; RE, right eye; SBCS, simultaneous bilateral cataract surgery; TN, Tamil Nadu; VA, visual acuity; VRC, voriconazole.

LC-MS/MS Analysis of CPA {#S2.SS4}
------------------------

Cyclopiazonic acid was extracted as described before by [@B11] with minor modifications. Briefly, the stationary cultures of *A. tamarii* isolates were grown in 2 ml of RPMI-1640 medium (pH 7.0; Sigma-Aldrich) supplemented with 10% heat inactivated fetal bovine serum (FBS; Gibco) at 37°C and simultaneously, in 2 ml of yeast extract sucrose (YES; pH 6.0) medium supplemented with soya peptone at 30°C. After 7 days of incubation, 2 ml of chloroform was added to each sample and vortexed for 30 s. Then, the mixtures were incubated for 2 h at room temperature and vortexed again for 30 s. In order to separate the aqueous and the organic phases, the samples were centrifuged at 9000 × *g* for 15 min. Then, the organic layer was transferred to a clean microcentrifuge tube, air dried and resuspended in 1 ml methanol. Mycelia from each sample were collected and dried in an oven at 70°C for 16 h to determine their dry weight. For the quantitation of CPA, 2 μl of extract was applied onto a Gemini NX C18 50 × 2 mm 3 μ (Phenomenex, United States) column built in a modular Shimadzu Nexera XR HPLC system (Shimadzu, Japan) equipped with a DGU-20A5R degasser, an LC-20AD XR quaternary pump, a SIL-20AXR autosampler and a CTO-10ASVP column thermostat. For the detection, a TSQ Quantum Access (Thermo Fisher Scientific, United States) triple quadrupole mass spectrometer (MS) was connected to the HPLC fitted with an electrospray ionization (ESI) source. The determination was performed according to [@B36] with minor modifications. The separation was carried out at 35°C at a flow rate of 0.2 ml/min using gradient elution from 5 mM ammonium acetate buffer/methanol (60/40, v/v) to 100% of methanol in 8 min time, than maintaining this percentage for 5 min and finally decreased to the starting value till pressure stabilization. The detection was in negative ESI, multiple reaction (MRM) mode using the *m/z* 335.1→141.3 (quanty) *m/z* 335.1→181.2 (qualy) transitions, where the collision gas pressure was fixed at 200 MPa and the collision energies (CE) were 30 V for each of the product ions. The MRM method consists of one scan event where the ion injection time was set to 100 ms with a total of 1 μcans/s. The parameters for the ESI interface were adjusted as follows: a spray voltage of 5.5 kV, a capillary temperature of 200°C, a tube lens offset of −167 V, a sheath gas flow rate of 0.6 l/min, and an auxiliary gas flow rate at 6 l/min. The divert valve was applied at 3.5 min and 8.5 min in order to maintain the instrument with a constant performance. The HPLC-MS instrument was controlled with the XCalibur v. 3.1 software (Thermo Fisher Scientific, United States), while the TraceFinder v. 4.1 software (Thermo Fisher Scientific, United States) was applied for data acquisition and evaluation.

Ethics Statement {#S2.SS5}
----------------

PM received an approval from the Institutional Review Board of the Aravind Eye Hospital for the project entitled "PCR based detection of *Fusarium* and *Aspergillus*, and evaluation of their antifungal susceptibilities from patients with keratomycosis attending a tertiary care eye hospital" in 2009. In order to protect the patients' anonymity, identifying information were not included in the manuscript.

Results {#S3}
=======

Patient Characteristics {#S3.SS1}
-----------------------

The brief summary of clinical data is available for all cases in [Table 2](#T2){ref-type="table"}. Out of the six isolates, five were isolated from patients residing in towns or cities of Tamil Nadu state, while one from a city of Kerala state. Most patients (*n* = 4) were female, the median age was 67.5. Majority of the infections (*n* = 5) was registered between June and September. The most frequently mentioned symptoms were pain, defective vision and redness. None of the patients had any relevant underlying conditions or reported immunosuppression. Half of the patients mentioned trauma as a predisposing factor, while the other three patients could not recall any injury prior to the infection. The severity of ulcers was recorded as mild in two and severe in four cases. In case of Patients 1, 2, 5, and 6, direct microscopic examination of KOH mounts and Gram-stained smears revealed the presence of fungal elements in the corneal scrapings. Gram-staining and 10% KOH wet mount showed a moderate number of Gram-negative bacilli with no fungal filaments in case of Patient 3, while the corneal scrapings of Patient 4 were negative for both fungal filaments and bacteria. However, cultures were subsequently positive for *Aspergillus* sp. in these latter cases as well.

### Therapy and Outcome {#S3.SS1.SSS1}

To sum up, the most common therapeutic approach was the combined topical application of natamycin, itraconazole and econazole eye drops supplemented with systemic ketoconazole treatment. Following this, the ulcer was completely healed in three patients. Evisceration was performed on one patient who developed severe ulcer and did not respond to antifungal therapy. Among the remaining two cases, one patient responded well to the therapy, whereas the other patient showed poor improvement, although both failed to report for the follow-up treatment. The detailed descriptions of each case are as follows:

Patient 1 and 2 were placed on natamycin 5% and econazole 2% eye drops half hourly, itraconazole 1% eye ointment and homatropine 1% eye drops thrice daily, ketoconazole (200 mg), and Dolomed (ibuprofen 600 mg + paracetamol 325 mg) twice daily. Once the culture results (*A. flavus* in both cases) were available, econazole 2% was replaced by clotrimazole 1% eye drops. The second follow-up visit examination of Patient 2 revealed a healing infiltrate. But in case of Patient 1, the corneal infiltrate was not responding to therapy, therefore a coexistent bacterial infection was suspected, and vancomycin 2% eye drops were added. Over the next 3 days the infiltrate resolved well and at the time of discharge 2 weeks after admission there was only a minimal deep stromal infiltrate.

Based on the results of the direct examinations of the scrapings, Patient 3 was started on ciprofloxacin 0.3% and tobramycin 0.3% eye drops six times a day along with homatropine 1% eye drops, oral ciprofloxacin (500 mg) twice a day and intravenous garamycin (80 mg) twice a day. However, the subsequent growth of fungal colonies on culture media was identified as *A. flavus*. The next day antibiotics were tapered to four times a day. Then, natamycin 5% and econazole 2% were added on an hourly basis along with itraconazole 1% eye ointment and homatropine 1% eye drops thrice daily, ketoconazole and Dolomed twice daily. Amphotericin B (50 μg/ml) half-hourly was added on the third day. However, by the fifth day the infection had progressed to involve the sclera and the patient complained of radiating pain to the scalp. A repeated ultrasonography showed reactionary vitritis with mild thickening of the retina*-*choroid*-*sclera complex. As there was no response to therapy and the visual prognosis was very poor, evisceration was offered to the patient and was done 5 days after presentation to the hospital.

Patient 4 was placed on natamycin 5% and moxifloxacin 0.5% eye drops hourly, along with itraconazole 1% eye ointment and homatropine 1% eye drops thrice daily, and Dolomed twice daily. Three days later, the infiltrate had resolved completely.

Patient 5 and 6 were placed on 5% natamycin and econazole 2% eye drops half hourly, itraconazole 1% eye ointment and homatropine 1% eye drops thrice daily; oral ketoconazole (200 mg) and Dolomed twice daily. Patient 5 showed good response to therapy while in case of Patient 6 the infiltrate continued to be active.

Molecular Identification {#S3.SS2}
------------------------

The six isolates of the study were initially identified as members of the genus *Aspergillus*, i.e., *Aspergillus* sp. (*n* = 1), *A. flavus* (*n* = 4), and *A. fumigatus* (*n* = 1) based on morphological examinations ([Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Molecular identification did not confirm these preliminary data, since both the ITS and the calmodulin sequences of the six isolates showed ≥99% similarity to sequences of the CBS 104.13 type strain of *A. tamarii*.

![Macro- and micromorphology (after lactophenol cotton blue staining) of *A. tamarii* **(A)** SZMC 2439 and **(B)** SZMC 2393 grown on potato dextrose agar plates for 5 days at 37°C. Scale bar: 50 μm.](fmicb-10-02249-g001){#F1}

Antifungal Drug Susceptibilities and Drug Interactions {#S3.SS3}
------------------------------------------------------

The obtained MIC values are summarized in [Table 3](#T3){ref-type="table"}. It could be noted that most of the MICs of fluconazole and natamycin were ≥64 μg/ml. Amphotericin B, clotrimazole, econazole, itraconazole, ketoconazole and terbinafine exerted good antifungal activity (MIC ≤ 2 μg/ml) against all the six isolates. Among them, terbinafine proved to be the most effective drug *in vitro* with a MIC of 0.008 μg/ml.

###### 

Minimum inhibitory concentration (MIC; μg/ml) values of antifungal agents for six *Aspergillus tamarii* isolates from human keratomycosis.

  **Isolate**              **SZMC 2393**   **SZMC 2404**   **SZMC 2428**   **SZMC 2434**   **SZMC 2438**   **SZMC 2439**   **MIC range (μg/ml)**   **GM MIC (μg/ml)**
  ------------------ ----- --------------- --------------- --------------- --------------- --------------- --------------- ----------------------- --------------------
  Antifungal agent   AMB   1               2               2               1               0.5             2               0.5--2                  1.3
                     CLT   0.25            0.5             1               1               0.25            0.25            0.25--1                 0.4
                     ECN   0.5             0.25            1               0.25            0.25            0.25            0.25--1                 0.4
                     FLC   \>64            \>64            \>64            \>64            \>64            \>64            \>64                    \>64
                     ITC   0.25            0.06            0.125           0.06            0.06            0.125           0.06--0.25              0.1
                     KTC   2               2               1               1               1               2               1--2                    1.4
                     NTM   ≥64             ≥64             ≥64             16              ≥64             ≥64             16 -- ≥64               ≥64
                     TRB   0.008           0.008           0.008           0.008           0.008           0.008           0.008                   0.008

AMB, amphotericin B; CLT, clotrimazole; ECN, econazole; FLC, fluconazole; GM, geometric mean; ITC, itraconazole; KTC, ketoconazole; NTM, natamycin; SZMC, Szeged Microbiological Collection, University of Szeged, Szeged, Hungary; TRB, terbinafine.

Most interactions between the tested antifungal drug combinations were indifferent ([Table 4](#T4){ref-type="table"}). For the combination of natamycin and econazole the FICIs ranged from 0.49 to 1.03, synergism was detected against one isolate (i.e., SZMC 2434). For econazole and itraconazole the FICIs were between 0.58 and 0.98, indicating no interactions between the two drugs. Synergism was detected between natamycin and itraconazole against *A. tamarii* SZMC 2428 and SZMC 2438 isolates (FICI = 0.49), while against the rest of the isolates, the FICIs were between 0.54 and 0.75 suggesting indifferent interactions.

###### 

*In vitro* combinations of antifungal drugs against six *Aspergillus tamarii* isolates from human keratomycosis.

  **Isolate**                  **FICI~min~/interpretation^∗^**                                       
  ------------------ --------- --------------------------------- -------- -------- -------- -------- --------
  Antifungal agent   ECN-ITC   0.72/I                            0.58/I   0.58/I   0.58/I   0.98/I   0.98/I
                     ECN-NTM   1.03/I                            0.61/I   1.03/I   0.49/S   0.54/I   0.98/I
                     ITC-NTM   0.66/I                            0.75/I   0.49/S   0.73/I   0.49/S   0.54/I

ECN, econazole; FICI

min

, minimal fractional inhibitory concentration index; ITC, itraconazole; NTM, natamycin; SZMC, Szeged Microbiological Collection, University of Szeged, Szeged, Hungary.

∗

I, indifference (0.5 \< FICI ≤ 4); S, synergism (FICI ≤ 0.5).

CPA-Producing Abilities {#S3.SS4}
-----------------------

The CPA-producing abilities of the six *A. tamarii* isolates were investigated in two different media, viz., YES supplemented with soya peptone and in RPMI-1640 medium supplemented with FBS. As shown in [Figure 2](#F2){ref-type="fig"}, four of the six isolates were capable to produce CPA in RPMI-1640 medium, while five isolates proved to be toxinogenic in YES. Although *A. tamarii* isolates grew poorly in RPMI-1640 medium (mean mycelial dry weight: 3.1 ± 1.0 mg), they produced a relatively high amount of CPA, ranging between 3.2 ± 1.0 μg/ml and 7.1 ± 4.7 μg/ml (mean CPA content: 6.5 ± 2.4 μg/ml). This is comparable to the CPA content of the YES samples, where CPA concentration ranged from 3.8 ± 4.1 μg/ml to 22.2 ± 16.7 μg/ml (mean CPA content: 12.5 ± 7.5 μg/ml). However, compared to RPMI-1640, this CPA concentration was attributed to a biomass higher than one order of magnitude in YES (mean mycelial dry weight: 51.7 ± 5.2 mg).

![Cyclopiazonic acid (CPA) producing ability (μg/mg mycelial dry weight) of the stationary cultures of *A. tamarii* isolates grown in yeast extract sucrose (YES) medium supplemented with soya peptone and in RPMI-1640 supplemented with fetal bovine serum (FBS) for 7 days in the dark. Results are the mean of two independent experiments with two individual replicates. The limit of quantitation was 500 ng/ml.](fmicb-10-02249-g002){#F2}

Discussion {#S4}
==========

The currently presented six cases and the previous reports of *A. tamarii* keratitis cases suggest that this species is a rare but regularly emerging pathogen of ocular infections. Although it was mainly reported from India before ([@B25]; [@B17]; [@B31]), its occurrence is not restricted to this country: a contact lens associated case from Spain, and four cases from Mexico have just been described recently ([@B14]; [@B1]). Seasonal variations are usually reported for keratitis. In a recent study from South India, most of the fungal isolates (80%) were obtained during the months of July--September ([@B39]). Similarly, [@B8] isolated the highest number of fungal strains between June and September. In accordance with these reports, five of the six *A. tamarii* isolates in this study were isolated within this 4- months period of the year. Environmental factors (e.g., humidity, temperature, wind, etc.), which are also responsible for these seasonal variations, may affect the geographical distribution of the infecting agents as well ([@B29]; [@B44]). Although aspergilli are more frequently reported from keratitis in North India, it is not the case with *A. tamarii*. This species is found mostly in tropical regions ([@B4]), and were reported more commonly from South India (*n* = 7; [@B25]; This study) than from the Northern part of the country ([@B17]).

Trauma was a key predisposing factor for the infection, as it was expected based on previous reports ([@B25]; [@B43]; [@B33]). Additionally, [@B33] listed co-existing ocular conditions and systemic diseases, such as diabetes mellitus and hypertension, among the risk factors for *Aspergillus* keratitis ([@B33]). Contact-lens associated cases of fungal keratitis are mainly reported from developed countries ([@B3]). Accordingly, the single case of *A. tamarii* keratitis in a contact lens wearer was reported from Spain ([@B14]).

Our results presented in [Table 1](#T1){ref-type="table"} underline the importance of using molecular identification methods in order to avoid misdiagnosis. Out of the six isolates in this study, five were identified at the species level based on morphological characteristics: four as *A. flavus*, and one as *A. fumigatus*, but none of them as *A. tamarii* ([Table 1](#T1){ref-type="table"}). In line with our experiences, [@B42] suggested that β-tubulin or the calmodulin genes are the best choice for identifying *A. flavus*, *A. nomius*, and *A. tamarii*. According to the authors, matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) might also be used for an accurate identification, however, this method requires a comprehensive database including different strains of a wide range of species. Similarly, the recent work of [@B14] concludes that MS combined with phenotypic analyses is a useful tool for the diagnosis of *A. tamarii* and other rare fungal pathogens. Recently, [@B1] also emphasized the importance of using molecular identification methods for the diagnosis of *A. tamarii* and other rare fungal pathogens. In this way, it is possible that studies using morphological identification methods alone for the diagnosis of *A. tamarii*, may not be completely reliable ([@B15]; [@B38]; [@B21]; [@B4]).

Antifungal susceptibility results of the present study are comparable to the reports listed in [Table 5](#T5){ref-type="table"}. Natamycin had no inhibitory effect on the *in vitro* growth of *A. tamarii* isolates of the study, which is similar to the results of [@B25] and [@B31] obtained for Indian isolates, but it is in contrast to the study of [@B1] who reported a lower MIC range of 4--16 μg/ml against four Mexican isolates. Despite the conflicting *in vitro* data, the vast majority of patients diagnosed with fungal keratitis is usually treated with natamycin eye drops alone or in combination with other topical antifungal drugs (e.g., itraconazole) ([@B17]) and it proved to have favorable effects in patients with *Aspergillus* keratitis previously ([@B20]). Natamycin was administered to eight patients diagnosed with *A. tamarii* keratitis as well ([Table 2](#T2){ref-type="table"}), raising the possibility that in combination with other antifungal agents (i.e., econazole and itraconazole) it could facilitate the reduction of the severity of infections. However, our *in vitro* observations could not support this theory, since the predominance of indifferent interactions was revealed between natamycin and econazole and between natamycin and itraconazole as well. Whereas, synergism was only detected between the combinations of natamycin-itraconazole and natamycin-econazole against three *A. tamarii* isolates.

###### 

Minimum inhibitory concentration (MIC; μg/ml) values of antifungal agents for the *Aspergillus tamarii* isolates reported previously from various human infections.

  **References**           **[@B25]*n* = 1 (*E*-test)**   **[@B6]*n* = 4 (*E*-test)**   **[@B14]*n* = 1 (E-test)**   **[@B31]*n* = 1 (BMD)**   **[@B1]*n* = 4 (BMD)**   **[@B9]**      
  ------------------ ----- ------------------------------ ----------------------------- ---------------------------- ------------------------- ------------------------ -------------- -------------
  Antifungal agent   AMB   0.125                          0.002--0.008                  0.25                         ≤0.5                      0.5--1 (0.59)            0.12           0.5--2
                     AND   --                             0.38--1                       --                           --                        --                       0.015--0.03    --
                     CLT   --                             --                            --                           ≤0.5                      --                       --             --
                     CSP   --                             0.016--0.25                   0.5                          --                        --                       ≤0.03          --
                     ECN   0.064                          --                            --                           ≥1                        --                       --             --
                     FLC   \>256                          \>32                          \>256                        --                        --                       --             --
                     ITC   0.064                          0.38--0.75                    --                           ≤0.25                     0.5--2 (0.84)            ≤ 0.03--0.06   0.5--1
                     KTC   0.25                           --                            --                           ≥1                        --                       --             --
                     MCF   --                             --                            --                           --                        --                       ≤0.03          0.06--0.25
                     NTM   \>1024                         --                            --                           ≥32                       4--8(5.65)               --             --
                     PSC   --                             0.125--0.94                   0.094                        --                        --                       ≤ 0.03--0.06   0.125--0.25
                     TRB   --                             --                            --                           --                        --                       --             --
                     VRC   0.125                          0.125--0.19                   --                           ≥1                        0.5--4 (0.133)           0.06--0.25     0.64--0.125

We only included data from papers using molecular or MALDI-TOF MS analyses for the confirmation of morphological identification. AMB, amphotericin B; AND, anidulafungin; BMD, broth microdilution; CLT, clotrimazole; CSP, caspofungin; ECN, econazole; FLC, fluconazole; ITC, itraconazole; KTC, ketoconazole; MCF, micafungin; NTM, natamycin; PSC, posaconazole; TRB, terbinafine; VRC, voriconazole.

Just as was the case with natamycin, fluconazole was not able to inhibit the *in vitro* growth of *A. tamarii* isolates in the current investigation ([Table 3](#T3){ref-type="table"}). However, this antifungal agent lessened the severity of *Aspergillus* keratitis in a rabbit model ([@B5]), the favorable outcome of fluconazole therapy in *Aspergillus* keratitis has not been confirmed in humans yet.

As it is shown in [Table 5](#T5){ref-type="table"}, beside the antifungal agents examined in this study, anidulafungin, caspofungin, micafungin, posaconazole and voriconazole also proved to be active against *A. tamarii in vitro* ([@B25]; [@B6]; [@B1]; [@B9]; [@B31]). Moreover, voriconazole had the best *in vitro* activity against *A. tamarii* isolates in the study of [@B1], and it was also used to treat successfully one out of the four patients diagnosed with *A. tamarii* keratitis without any surgery. In the present study, terbinafine was the most active antifungal agent against all the six isolates. Its *in vitro* efficiency against *A. tamarii* has not been investigated yet ([Table 5](#T5){ref-type="table"}), but the topical application of 0.25% terbinafine eye drops on fungal -- mainly *Aspergillus* and *Fusarium* -- keratitis has been compared to 5% natamycin in a retrospective clinical study before ([@B30]). Although the majority of patients showed favorable response to terbinafine therapy, they needed a longer treatment course compared to the patients in the natamycin-group. Nonetheless, terbinafine eye drops might be a good alternative in the future for the treatment of fungal keratitis, especially in countries where natamycin or voriconazole is not available.

Our tests revealed, that the antifungal drug susceptibility profile of *A. tamarii* is similar to those of the other keratitis-derived members of section *Flavi* ([@B6]). In the present study, only the MICs of amphotericin B (MIC range: 0.5--2 μg/ml) differed significantly from the previously published values for *A. flavus* (MIC range: 2--12 μg/ml; [@B6]). Although the CLSI epidemiological cut-off (ECOFF) values are not available yet for *A. tamarii*, the ECOFF of amphotericin B for other aspergilli (2 μg/ml for *A. fumigatus*, *A. flavus*, *A. niger*; 4 μg/ml for *A. terreus*) and the aforementioned MIC range obtained for *A. tamarii* isolates suggest, that the members of this species may respond well to an amphotericin B therapy ([@B28]).

Treatment options seem to vary between countries ([Table 2](#T2){ref-type="table"}; [@B25]; [@B14]; [@B1]). In India, the combination of topical natamycin, econazole and itraconazole supplemented with systemic ketoconazole was the most common treatment of choice (this study; [@B25]). In Spain, the patient's antifungal therapy started with topical 1% voriconazole and systemic liposomal amphotericin B, and after he was discharged, it was changed to topical 5% natamycin and 1% voriconazole, and oral voriconazole (200 mg/12 h) ([@B14]). In Mexico, 1% voriconazole was the topical drug of choice ([@B1]), while systemic therapy was applied in case of one patient who received oral itraconazole (200 mg/24 h). Improvement was detected in one patient without surgery, while it was necessary in the other three patients ([@B1]). The patient's condition in Spain was also improved ([@B14]). Whereas in India, five patients showed improvement but two showed no response to therapy despite the similar combinations of antifungal drugs applied in all the seven cases (this study; [@B25]).

Cyclopiazonic acid serves as a key plant pathogenicity factor for the closely related species *A. flavus* ([@B10]), and it may also influence the virulence of aspergilli in animal and human hosts by contributing to the deterioration of the patient's condition through its neurotoxic and immunomodulatory effects ([@B22]; [@B10]). Production of CPA by *A. tamarii* was firstly reported by [@B16], where, 96% (22/23) of the investigated isolates were able to produce this mycotoxin. Similarly, the current study confirmed the CPA-producing ability for five out of the six examined keratitis isolates. In contrast to the present study, [@B45] observed that *A. tamarii* strains produced a lower amount (1.74--2.49 ppm) of CPA in modified Czapek Dox medium. Whereas, in comparison to *A. flavus* isolates (32.5 ± 2.5 -- 57.9 ± 4.1 μg/ml in YES with soytone) ([@B11]), the currently presented six *A. tamarii* isolates possessed a lower CPA-productivity in modified YES and RPMI-1640 media as well. Comparable results of CPA production by other clinical *A. tamarii* isolates are not available in the literature.

In conclusion, our results confirm that *A. tamarii* is an emerging human pathogenic species associated with keratomycoses in India. The number of studies on *A. tamarii* infections, where both molecular identification and antifungal susceptibility testing were performed and clinical data are also available, is very small ([@B25]; [@B1]; this study). However, these researches are crucial to answer the question whether the use of molecular identification approaches in clinical practice could improve the outcome of fungal eye infections. *In vitro* antifungal susceptibility testing revealed that terbinafine might be a good alternative as a topical eye drop or ointment to treat *A. tamarii* keratitis in the future. In addition, we also revealed that drug interactions between the most commonly applied antifungal agents were mainly indifferent, while synergistic interactions were registered in three cases. Although *A. tamarii* seems to respond well to antifungal agents and their combinations *in vitro*, poor outcomes have been registered as well among the six presented cases. This fact indicates, that not just the treatment of choice, but the unique characteristics of the patient and the infecting strain (e.g., its mycotoxin producing ability) might also affect the final outcome of a therapy. Our observations on the ability of *A. tamarii* strains to produce a high amount of CPA despite their poor growth in RPMI-1640 will probably facilitate further studies to examine whether this mycotoxin is able to promote tissue damage and exacerbate the patient's condition during an eye infection.
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